课题基金 / 基金详情

Neutralizing Anti-HGF mAbs and CNS Malignancy

Neutralizing Anti-HGF mAbs and CNS Malignancy
中和抗 HGF 单克隆抗体和中枢神经系统恶性肿瘤
批准号:
7299276
负责人:
John J Laterra
金额:
$30.58万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-08-01 至 2011-07-30

项目摘要

项目成果

John J Laterra的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):胶质瘤和许多其他实体恶性肿瘤的恶性进展和生存率低与跨膜受体酪氨酸激酶c-Met及其分泌配体肝细胞生长因子(HGF)的过度表达有关。HGF和c-Met越来越被视为有前途的治疗靶点,这是由于这些临床关联以及它们的多功能自分泌和旁分泌肿瘤促进活性,包括直接刺激肿瘤细胞生长、肿瘤细胞对细胞毒性疗法的抗性、肿瘤细胞迁移/侵袭和肿瘤血管生成。我们已经表明,中和性抗HGF单克隆抗体(L2 G7)特异性且有效地阻断HGF功能,并抑制表达HGF的原位人神经胶质瘤异种移植物(包括原发性神经胶质瘤异种移植物)的生长,并延长动物存活。L2 G7抑制胶质瘤Akt和MAP-激酶活性、肿瘤血管生成、增殖指数,并增加肿瘤凋亡指数。为了最佳地开发用于恶性脑肿瘤的抗HGF mAb疗法,必须回答许多问题。未回答的问题包括:L2 G7交付的最佳途径是什么?将L2 G7与标准细胞毒性疗法相结合有哪些益处?联合治疗能否根据HGF:c-Met通路抑制的动力学进行优化?我们能否识别出对L2 G7治疗有或多或少反应的胶质瘤亚群?这项研究将使用创新的异种移植模型系统,以及一系列互补的分子,生物和成像肿瘤反应终点来回答这些问题和相关问题。我们的具体目标是:(1)确定抗HGF HuL 2G 7在神经胶质瘤异种移植物中的直接瘤内对流增强递送相对于全身递送的相对功效,(2)确定HuL 2G 7是否增强神经胶质瘤异种移植物中的放射和/或化学疗法的功效,和(3)鉴定用于预测神经胶质瘤对HGF:c-Met途径抑制的敏感性/抗性的临床上可翻译的分子标志物。阳性结果将阐明抗HGF治疗剂的机制、给药方案和分子/生物学反应标准,这些是最佳开发用于CNS癌症的抗HGF L2 G7和潜在的其他HGF:c-Met通路抑制剂所必需的。这些发现也将大大有助于其他基于抗体的治疗方法在脑癌中的应用。肝细胞生长因子(HGF)是一个很有前途的治疗靶点,对最常见的原发性中枢神经系统恶性肿瘤,如胶质母细胞瘤和髓母细胞瘤和脑转移瘤。本研究将探讨如何最好地使用中和抗HGF单克隆抗体来抑制实验性脑肿瘤的生长。还将确定用于预测肿瘤敏感性和评估对HGF抑制的抗肿瘤反应的组织学、生物化学和遗传标记物。结果将影响HGF抑制剂如何用于脑肿瘤患者。
英文摘要
DESCRIPTION (provided by applicant): Malignant progression and poor survival in glioma and many other solid malignancies are linked with over-expression of the transmembraneous receptor tyrosine kinase c-Met and its secreted ligand hepatocyte growth factor (HGF). HGF and c-Met are increasingly seen as promising therapeutic targets due to these clinical associations and to their multifunctional autocrine and paracrine tumor promoting activities that include the direct stimulation of tumor cell growth, tumor cell resistance to cytotoxic therapy, tumor cell migration/invasion, and tumor angiogenesis. We have shown that the neutralizing anti- HGF monoclonal antibody (L2G7) specifically and potently blocks HGF functions and inhibits the growth of HGF-expressing orthotopic human glioma xenografts, including primary glioma xenografts, and prolonged animal survival. L2G7 inhibits glioma Akt and MAP-kinase activity, tumor angiogenesis, proliferation index, and increases tumor apoptosis index. Numerous questions must be answered in order to optimally develop anti-HGF mAb therapy for malignant brain tumors. Unanswered questions include -What is the best route of L2G7 delivery? What are the benefits of combining L2G7 with standard cytotoxic modalities? Can combination therapies be optimized based on the dynamics of HGF:c-Met pathway inhibition? Can we identify subsets of gliomas that are more or less likely to respond to L2G7 therapy? This research will use innovative xenograft model systems, and an array of complementary molecular, biological, and imaging tumor response endpoints to answer these and related questions. Our specific aims are: (1) To determine the relative efficacy of direct intratumoral convection enhanced delivery vs. systemic delivery of anti-HGF HuL2G7 in glioma xenografts, (2) To determine if HuL2G7 enhances the efficacy of radiation and/or chemotherapy in glioma xenografts, and (3) To identify clinically translatable molecular markers for predicting glioma sensitivity/resistance to HGF:c-Met pathway inhibition. Positive results will elucidate mechanisms of anti- HGF therapeutics, dosing schemes, and molecular/biological response criteria necessary for optimally developing anti-HGF L2G7 and potentially other HGF:c-Met pathway inhibitors .for CNS cancer. Findings will also contribute substantially to the application of other antibody-based therapeutics to brain cancer. Hepatocyte growth factor (HGF) is a promising therapeutic target for the most common primary CNS malignancies such as glioblastoma and medulloblastoma and brain metastases. This research will examine how to best use a neutralizing anti-HGF monoclonal antibody to inhibit experimental brain tumor growth. Histological, biochemical, and genetic markers for predicting tumor sensitivity and assessing anti-tumor responses to HGF inhibition will also be determined. Results will impact on how HGF inhibitors are used in brain tumor patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tet2 regulation and function in glioma cell phenotype reprogramming
Tet2 regulation and function in glioma cell phenotype reprogramming
Tet2 regulation and function in glioma cell phenotype reprogramming
Tet2 regulation and function in glioma cell phenotype reprogramming
海外基金